SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Welcome to the GENT board. GENT has the first drug for VOD.
An SI Board Since July 2006
Posts SubjectMarks Bans Symbol
408 17 0 GENT
Emcee:  rareearth42 Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
233Brean Capital started coverage with a buy and target of 16. Give df a 65% chancIRWIN JAMES FRANKEL-12/1/2012
232nasdaq.com Blackrock, FMR and Morgan Stanley etc. added over 400K shares. IRWIN JAMES FRANKEL-11/15/2012
231Again I searched and couldn't find the issue(s). Given the delays the compaghmm-10/10/2012
230Gentium Receives Second List of Outstanding Issues From the EMA's CHMP for DIRWIN JAMES FRANKEL-10/10/2012
229Gentium Appoints Biologix FZCo as Exclusive Distributor of Defibrotide in the MiIRWIN JAMES FRANKEL-10/4/2012
228>> I tried searching on the EMA website to see what the outstanding issuesIRWIN JAMES FRANKEL-9/26/2012
227>> News can't be good but doesn't this look fairly routine? AnothIRWIN JAMES FRANKEL-9/26/2012
226Thanks. Still think approval is by far the most probably outcome but was hopingfred hayes-9/26/2012
225I tried searching on the EMA website to see what the outstanding issues were butghmm-9/26/2012
224Thanks for posting that. News can't be good but doesn't this look fairlyfred hayes-9/26/2012
223Gentium Provides Update on the Review of Defibrotide Marketing Authorization AppIRWIN JAMES FRANKEL-9/26/2012
222 GENTIUM S.p.A. Consolidated Balance Sheets (Amounts in thousands except shareIRWIN JAMES FRANKEL-9/13/2012
221Gentium Reports First Half 2012 Financial Results [graphic]Press Release: GentiuIRWIN JAMES FRANKEL-9/13/2012
220Gentium to Present Oral Explanations to EMA's CHMP for Defibrotide MAA [grapIRWIN JAMES FRANKEL-9/11/2012
219Gentium was listed as presenting this morning at the wedbush conference wsw.com ghmm-8/15/2012
218Gentium updated their events page gentium.com and are scheduled to present at soghmm-7/18/2012
217Gentium Reports First Quarter Financial Results [graphic]Press Release: Gentium IRWIN JAMES FRANKEL-5/17/2012
216Gentium Receives Day 180 List of Outstanding Issues From the CHMP for DefibrotidIRWIN JAMES FRANKEL-5/4/2012
215If someone is going to invest into making a Biosimilar (I've seen estimates ghmm-4/6/2012
214>>do they control the IP in these indications? From a recent report: GenIRWIN JAMES FRANKEL-4/6/2012
213I haven't checked, and am busy, so I'm not going to, but the question thtuck-4/6/2012
212They certainly have higher priorities. But second (GvH) or third (MM) uses for IRWIN JAMES FRANKEL-4/6/2012
211Admittedly I haven't looked very much but I certainly don't hear currentghmm-4/5/2012
210ncbi.nlm.nih.gov Expert Opin Biol Ther. 2012 Mar;12(3):353-61. Epub 2012 Jan 28IRWIN JAMES FRANKEL-4/5/2012
209I am not familiar with this journal but it would seem to be the appropriate audighmm-3/20/2012
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News